ES2503621T3 - Métodos para detectar trastornos autoinmunitarios - Google Patents

Métodos para detectar trastornos autoinmunitarios Download PDF

Info

Publication number
ES2503621T3
ES2503621T3 ES12179717.9T ES12179717T ES2503621T3 ES 2503621 T3 ES2503621 T3 ES 2503621T3 ES 12179717 T ES12179717 T ES 12179717T ES 2503621 T3 ES2503621 T3 ES 2503621T3
Authority
ES
Spain
Prior art keywords
methods
autoimmune disorders
subject
genes
cig5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12179717.9T
Other languages
English (en)
Inventor
Alexander Abbas
Barmak Modrek
Michael J. Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2503621T3 publication Critical patent/ES2503621T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para diagnosticar lupus eritematoso sistémico en un sujeto, comprendiendo dicho método determinar si el sujeto comprende una célula que expresa una combinación de genes a un nivel superior al nivel de expresión de los genes respectivos en una muestra de referencia normal, en donde la combinación de genes incluye IFI44L, CIG5 e IFI44, y en el que la presencia de expresión aumentada de IFI44L, CIG5 e IFI44 en dicha célula indica que el sujeto tiene lupus eritematoso sistémico

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65

Claims (1)

  1. imagen1
ES12179717.9T 2006-04-24 2007-04-24 Métodos para detectar trastornos autoinmunitarios Active ES2503621T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79439306P 2006-04-24 2006-04-24
US794393P 2006-04-24

Publications (1)

Publication Number Publication Date
ES2503621T3 true ES2503621T3 (es) 2014-10-07

Family

ID=38340088

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12179733.6T Active ES2462526T3 (es) 2006-04-24 2007-04-24 Métodos y composiciones para detectar trastornos autoinmunitarios
ES09003931.4T Active ES2471444T3 (es) 2006-04-24 2007-04-24 Métodos y composiciones para detectar trastornos autoinmunitarios
ES12179717.9T Active ES2503621T3 (es) 2006-04-24 2007-04-24 Métodos para detectar trastornos autoinmunitarios

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES12179733.6T Active ES2462526T3 (es) 2006-04-24 2007-04-24 Métodos y composiciones para detectar trastornos autoinmunitarios
ES09003931.4T Active ES2471444T3 (es) 2006-04-24 2007-04-24 Métodos y composiciones para detectar trastornos autoinmunitarios

Country Status (11)

Country Link
US (5) US20080057503A1 (es)
EP (4) EP2044213A2 (es)
JP (2) JP5784272B2 (es)
KR (1) KR101464386B1 (es)
CN (2) CN101473045B (es)
AU (1) AU2007244868B2 (es)
CA (1) CA2649918C (es)
DK (1) DK2557180T3 (es)
ES (3) ES2462526T3 (es)
PL (1) PL2557180T3 (es)
WO (1) WO2007127756A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044213A2 (en) * 2006-04-24 2009-04-08 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US20100285458A1 (en) * 2007-01-25 2010-11-11 Danute Bankaitis-Davis Gene Expression Profiling for Identification, Monitoring, and Treatment of Lupus Erythematosus
EP2167679A4 (en) * 2007-07-12 2011-01-12 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR DIAGNOSIS AND ASSESSMENT OF INFLAMMATORY MUSCLE DISEASES
AU2009246180B2 (en) 2008-05-14 2015-11-05 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
WO2009155559A1 (en) * 2008-06-20 2009-12-23 Medimmune Llc Interferon alpha-induced pharmacodynamic markers
WO2011085653A1 (zh) * 2010-01-12 2011-07-21 中国科学院上海生命科学研究院 用于鉴定和治疗葛瑞夫兹氏病的方法和试剂盒
WO2011133474A2 (en) * 2010-04-18 2011-10-27 Beth Israel Deaconess Medical Center Methods of predicting predisposition to or risk of kidney disease
ES2372762B1 (es) * 2010-07-02 2012-11-28 Consejo Superior De Investigaciones Científicas (Csic) Método y kit para la detección de la activación de interferón y la respuesta inflamatoria independiente de interferón.
WO2012074396A1 (en) * 2010-11-30 2012-06-07 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle
AU2012249601A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2014032899A1 (en) * 2012-08-31 2014-03-06 Novo Nordisk A/S Diagnosis and treatment of lupus nephritis
US9867055B2 (en) * 2014-04-30 2018-01-09 Qualcomm Incorporated Techniques for coordinating communications over an unlicensed radio frequency spectrum band
CN105420347A (zh) * 2014-08-21 2016-03-23 南京大学医学院附属鼓楼医院 一种用于系统性红斑狼疮的基因诊断试剂盒
WO2016026258A1 (en) * 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 系统性红斑狼疮生物标志物及其诊断试剂盒
KR101795689B1 (ko) * 2015-04-30 2017-11-30 경희대학교 산학협력단 혈관 협착 질환 진단용 마커 및 이의 용도
CN106520970B (zh) * 2016-11-24 2018-08-07 汕头大学医学院第一附属医院 用于诊断脑卒中的标志物
EP3450981A1 (en) * 2017-08-28 2019-03-06 Trizell GmbH Btnl8 as a marker for tregs
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
AU2019266226A1 (en) 2018-05-09 2020-12-03 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
CN111351946B (zh) * 2020-03-19 2023-08-18 中南大学湘雅二医院 用于红斑狼疮分型的AIM2+CD4+Trm细胞检测试剂盒及其应用
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
EP1037995A1 (en) 1997-12-08 2000-09-27 Genentech, Inc. Human interferon-epsilon: a type 1 interferon
WO2000022093A2 (en) 1998-09-23 2000-04-20 Cleveland Clinic Foundation Novel interferon stimulated and repressed genes
EP1234060A2 (en) * 1999-11-30 2002-08-28 OXO Chemie AG Evaluating and predicting clinical outcomes by gene expression analysis
CA2402525A1 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
IL155450A0 (en) * 2000-10-20 2003-11-23 Expression Diagnostics Inc Leukocyte expression profiling
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CN1120368C (zh) * 2001-02-28 2003-09-03 崔京涛 一种检测脱氧核糖核蛋白抗体的免疫乳胶试剂的制备方法
US20030148298A1 (en) * 2001-04-03 2003-08-07 O''toole Margot Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
CN1348104A (zh) * 2001-10-09 2002-05-08 上海生物芯片有限公司 系统性红斑狼疮快速检测生物芯片
EP1511690A4 (en) 2002-05-16 2007-10-24 Univ Vanderbilt TECHNIQUE FOR PREDICTING AUTOIMMUNE DISEASES
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US7118865B2 (en) * 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
EP1599498A2 (en) * 2003-03-03 2005-11-30 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
WO2004094473A2 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US20060100132A1 (en) * 2003-06-06 2006-05-11 Brit Corneliussen Method for diagnosing inflammatory bowel disease
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1889978A (zh) * 2003-12-10 2007-01-03 米德列斯公司 干扰素α抗体及其用途
WO2005123113A2 (en) 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
EP1793845A2 (en) * 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
EP1789798A4 (en) * 2004-08-13 2009-02-18 Xceed Molecular Corp MARKER FOR DETECTION OF AUTOIMMUNE DISEASES
US7571055B2 (en) * 2004-10-13 2009-08-04 Regents Of The University Of Minnesota Systemic lupus erythematosus
WO2006088438A1 (en) 2005-02-14 2006-08-24 Applera Corporation Biomarkers for interferon-alpha response in hepatitis c virus infected patients
CA2614455A1 (en) 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
EP2044213A2 (en) 2006-04-24 2009-04-08 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
AU2012249601A1 (en) 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases

Also Published As

Publication number Publication date
DK2557180T3 (da) 2014-09-15
WO2007127756A3 (en) 2008-01-24
EP2080814B1 (en) 2014-04-23
PL2557180T3 (pl) 2014-12-31
US8962249B2 (en) 2015-02-24
EP2044213A2 (en) 2009-04-08
CA2649918C (en) 2018-12-11
EP2080814A2 (en) 2009-07-22
EP2080814A3 (en) 2009-11-18
AU2007244868B2 (en) 2013-11-21
JP2009534053A (ja) 2009-09-24
CA2649918A1 (en) 2007-11-08
JP5912097B2 (ja) 2016-04-27
US20120295799A1 (en) 2012-11-22
AU2007244868A1 (en) 2007-11-08
EP2557180B1 (en) 2014-07-09
ES2462526T3 (es) 2014-05-23
US9139878B2 (en) 2015-09-22
KR20090013796A (ko) 2009-02-05
JP2013240336A (ja) 2013-12-05
WO2007127756A2 (en) 2007-11-08
CN106086175A (zh) 2016-11-09
EP2537943B1 (en) 2014-03-12
EP2557180A1 (en) 2013-02-13
US20130338019A1 (en) 2013-12-19
CN106086175B (zh) 2020-03-03
KR101464386B1 (ko) 2014-11-26
EP2537943A1 (en) 2012-12-26
US20100267033A1 (en) 2010-10-21
CN101473045B (zh) 2016-08-03
ES2471444T3 (es) 2014-06-26
US20160097098A1 (en) 2016-04-07
CN101473045A (zh) 2009-07-01
US20080057503A1 (en) 2008-03-06
JP5784272B2 (ja) 2015-09-24

Similar Documents

Publication Publication Date Title
ES2503621T3 (es) Métodos para detectar trastornos autoinmunitarios
ES2541178T3 (es) Método de detección de cáncer colorrectal
WO2011106738A3 (en) Use of tcr clonotypes as biomarkers for disease
CL2011002973A1 (es) Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa.
GB2467704B (en) A method for determining a profile of recombined DNA sequences in T-cells and/or B-cells
ES2527776T3 (es) Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin
ES2656962T3 (es) Métodos para evaluar la receptividad del endometrio de una paciente
MX2020004617A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
JP2013518244A5 (es)
EP2804001A3 (en) Methods for diagnosing prostate carcinomas
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
EP3318643A3 (en) Methods and compositions for identifying and treating lupus
EP2891885A3 (en) Diabetes-related biomarkers and methods of use thereof
BR112015014821A2 (pt) método e mídia legível por computador
GB2475662A (en) Automated elevator fixture addressing
WO2010061283A8 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2012074972A3 (en) Non-destructive testing methods for fuel cell interconnect manufacturing
EP3182126A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
UY33058A (es) Detección del evento de soja aad-12 416
MY187907A (en) Methods and snp detection kits for predicting palm oil yield of a test oil palm plant
WO2008017984A3 (en) A method, apparatus, graphical user interface, computer-readable medium, and use for quantification of a structure in an object of an image dataset
ES2544984T3 (es) Detección de la descomposición de enzimas en un elemento de ensayo por liberación controlada de un analito protegido
Bajaj et al. MELD score does not discriminate against patients with hepatic encephalopathy
EA200970256A1 (ru) Биомаркеры для определения функции печени